Clinical research in Asia is at an inflection point. The region has long been recognised as a strategically important geography for global drug development — large patient populations, high disease burden across multiple therapeutic areas, and regulatory authorities that have, over the past decade, progressively aligned with international standards. But the infrastructure model that has underpinned clinical trial conduct in Asia for the past thirty years — centralised, site-dependent, hospital-anchored — is being challenged by a shift that was accelerated dramatically by the pandemic and has not reversed since.
Decentralised clinical trials are not a new concept. The theoretical case for conducting trial activities closer to patients, reducing the burden of site visits, and leveraging digital health technologies to capture data remotely has been discussed in the clinical research literature since at least 2010. What changed between 2020 and 2026 is that the theoretical case became operational reality — and Asia, with its particular combination of demographic scale, digital infrastructure maturity, and regulatory evolution, is positioned to benefit from that shift in ways that are only beginning to be fully understood.
📱 What Decentralised Clinical Trials Actually Mean in Practice
The term decentralised clinical trials covers a spectrum of trial designs rather than a single model. At one end of the spectrum, fully decentralised trials conduct all or nearly all trial activities remotely — recruitment through digital channels, consent through eConsent platforms, investigational product delivery direct to participants, and data collection through wearable devices, electronic patient-reported outcomes (ePRO), and telemedicine consultations. At the other end, hybrid decentralised trials retain a central investigational site for activities that genuinely require physical presence — baseline assessments, complex procedures, safety monitoring — while decentralising routine follow-up visits, data collection, and participant support.
In practice, the majority of decentralised clinical trials currently operating globally are hybrid models. A 2025 survey of clinical operations leaders across 47 global pharmaceutical and biotechnology companies found that 73% of trials described as “decentralised” by the sponsoring organisation retained at least some site-based activities, with fully remote trial designs accounting for only 12% of the total.
This distinction matters for Asia specifically, because the regulatory frameworks of the region’s major clinical trial markets — including Japan’s PMDA, China’s NMPA, South Korea’s MFDS, Taiwan’s TFDA, and Singapore’s HSA — have developed their DCT guidance in ways that generally support hybrid models while maintaining requirements for investigator oversight and site accountability that make fully remote designs more challenging to implement.
📊 The Asian DCT Landscape: Where the Data Points
The growth trajectory of decentralised clinical trials in Asia is measurable and accelerating. According to a 2025 analysis of clinical trial registrations across ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform, the number of trials registered in Asian markets incorporating at least one decentralised element increased by 187% between 2021 and 2025 — compared to a 94% increase in North America and a 112% increase in Europe over the same period.
The therapeutic areas driving DCT adoption in Asia reflect both global trends and region-specific disease burden priorities:
- Oncology — 34% of Asian DCTs, driven by the high prevalence of gastrointestinal, lung, and hepatocellular cancers across the region and the practical challenges of frequent site visits for patients undergoing active treatment
- Cardiovascular and metabolic disease — 22%, reflecting the substantial and growing burden of type 2 diabetes, hypertension, and dyslipidaemia across South and Southeast Asia
- Rare diseases — 18%, where the geographic dispersion of eligible patients across large territories makes centralised site models particularly inefficient
- Neurology and CNS — 14%, including Alzheimer’s disease, Parkinson’s disease, and epilepsy, where continuous remote monitoring offers genuine scientific advantages over periodic site assessments
- Respiratory — 12%, accelerated by the COVID-19 pandemic and sustained by ongoing interest in chronic obstructive pulmonary disease and asthma research
The patient recruitment data is particularly compelling. A 2024 benchmarking study comparing recruitment performance in matched conventional and decentralised trial designs across Asian markets found that DCT designs achieved 43% faster recruitment to target enrolment, 31% lower screen failure rates, and 28% higher trial completion rates compared to conventional site-based designs in the same therapeutic areas and geographies.
🌏 Regulatory Evolution Across Key Asian Markets
The regulatory landscape for decentralised clinical trials in Asia has evolved substantially since 2022, though the pace and character of that evolution varies considerably across markets.
Japan has been among the most proactive. The PMDA published its DCT guidance framework in 2023, explicitly endorsing hybrid trial designs and providing detailed guidance on eConsent requirements, remote monitoring standards, and the conditions under which direct-to-patient investigational product shipment is permissible. A 2025 review of PMDA interactions on DCT-related submissions found that 89% of sponsors who engaged with the agency through pre-submission consultation received positive feedback on their proposed DCT design elements.
China has moved more cautiously but meaningfully. The NMPA’s 2024 technical guidance on remote clinical trial conduct acknowledges the legitimacy of decentralised elements while maintaining requirements for investigator physical presence at key trial milestones and imposing data localisation requirements that affect the architecture of DCT technology platforms operating in the Chinese market. Despite these constraints, the number of DCT-incorporating trials registered in China grew by 156% between 2022 and 2025.
South Korea and Singapore have emerged as regional leaders in DCT regulatory clarity. The MFDS published comprehensive DCT guidance in 2023 that is broadly aligned with the EMA’s 2022 reflection paper on decentralised elements in clinical trials, while Singapore’s HSA has actively positioned the country as a DCT innovation hub, with a dedicated regulatory sandbox programme that has supported 23 novel DCT design applications since its launch in 2023.
Southeast Asian markets — including Thailand, Malaysia, Indonesia, and the Philippines — are at earlier stages of DCT regulatory development, but all four have initiated formal stakeholder consultation processes on DCT frameworks, with Thailand’s FDA and Malaysia’s NPRA both expected to publish draft guidance by the end of 2026.
🔧 The Technology Infrastructure Question
Decentralised clinical trials are only as effective as the digital infrastructure that supports them. In Asia, that infrastructure picture is genuinely mixed — and understanding the variation is essential for trial design decisions.
Smartphone penetration across the region’s major clinical trial markets is high and continues to rise. As of 2025, smartphone ownership among adults aged 18–65 exceeds 91% in South Korea, 88% in Japan, 85% in China’s urban population, and 79% in Singapore. These figures support the use of ePRO platforms, telemedicine consultations, and digital recruitment channels in these markets with reasonable confidence.
The picture is more complex in rural and semi-urban populations across Southeast Asia, where smartphone penetration remains lower, connectivity is less reliable, and digital health literacy varies considerably. A 2025 study of DCT participant experience across five Southeast Asian countries found that 37% of participants in rural areas reported technology-related difficulties that affected their trial participation — compared to 11% in urban centres in the same countries.
This urban-rural digital divide has direct implications for the equity dimensions of DCT design in Asia. Trials that rely exclusively on smartphone-based data collection and telemedicine consultation risk systematically excluding the rural populations that carry the highest burden of many of the diseases that Asian DCTs are designed to study. Hybrid designs that retain accessible site options for participants who cannot or prefer not to engage digitally are not just a regulatory preference — they are an equity imperative.
💡 The Strategic Opportunity: What Asian DCTs Make Possible
The most significant opportunity that decentralised clinical trials create for Asian drug development is not operational efficiency — though the recruitment and retention data is compelling. It is access to patient populations that conventional site-based trial models have systematically failed to reach.
Asia’s demographic scale is well understood. Less well appreciated is the degree to which that scale has been inaccessible to clinical research because of the practical barriers that site-based trial participation imposes — travel time and cost, work and family commitments, the concentration of investigational sites in major urban centres that are geographically distant from large patient populations.
A 2024 modelling study estimated that DCT designs could increase the addressable patient population for clinical trials in Asia by 2.3 times compared to conventional site-based designs — not by changing eligibility criteria, but simply by removing the participation barriers that site-based models impose. For rare disease programmes, where finding sufficient eligible patients is frequently the primary constraint on trial feasibility, that multiplier has transformative implications.
The data quality opportunity is equally significant. Wearable devices and continuous remote monitoring generate data at a density and temporal resolution that periodic site visits cannot match. For endpoints that are inherently dynamic — blood glucose variability, cardiac rhythm, gait and movement parameters, sleep architecture — the scientific value of continuous remote data collection is not merely convenient. It is genuinely superior to the snapshot data that site-based assessments provide.
🏁 Building DCTs That Work in Asia
The organisations navigating Asian DCT implementation most successfully share a consistent approach. They design for the hybrid model from the outset rather than attempting to retrofit decentralised elements onto a conventional trial architecture. They engage regulatory authorities early — particularly in Japan, China, and South Korea, where pre-submission consultation on DCT design elements is both available and genuinely informative. They invest in participant digital literacy support rather than assuming it. And they treat the urban-rural infrastructure gap as a design constraint to be addressed, not a limitation to be ignored.
Decentralised clinical trials in Asia are not a future possibility. They are a present reality, growing at nearly twice the global average rate, supported by an evolving regulatory framework, and backed by participant recruitment and retention data that the conventional trial model cannot match.
The infrastructure is maturing. The regulatory clarity is arriving. The patient populations are waiting.
